CIK 0001593899 · Non-accelerated filer<br>Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 460574869
- Phone
- (857) 284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-11-03 | BERGER FRANKLIN M Director | Conversion · Series D Convertible Preferred Stock | −60,540 | 0 | ||
| 2020-11-03 | BERGER FRANKLIN M Director | Conversion · Series D-1 Convertible Preferred Stock | −35,474 | 0 | ||
| 2020-11-03 | Corcoran Andrea See Remarks | Conversion | +133,004 | 633,004 | ||
| 2020-11-03 | Corcoran Andrea See Remarks | Conversion · Series A Convertible Preferred Stock | −100,000 | 0 | ||
| 2020-11-03 | Corcoran Andrea See Remarks | Conversion · Series B Convertible Preferred Stock | −33,004 | 0 | ||
| 2020-11-03 | Sommadossi Jean-Pierre President, CEO, and Chairman | Conversion | +750,000 | 5,925,000 | ||
| 2020-11-03 | Sommadossi Jean-Pierre President, CEO, and Chairman | Conversion · Series A Convertible Preferred Stock | −750,000 | 0 | ||
| 2020-11-03 | Chu Chung K. 10% owner | Conversion | +176,862 | 1,176,862 | ||
| 2020-11-03 | Chu Chung K. 10% owner | Conversion · Series A Convertible Preferred Stock | −100,000 | 0 | ||
| 2020-11-03 | Chu Chung K. 10% owner | Conversion · Series B Convertible Preferred Stock | −33,003 | 0 | ||
| 2020-11-03 | Chu Chung K. 10% owner | Conversion · Series C Convertible Preferred Stock | −43,859 | 0 | ||
| 2020-11-03 | Vavricka John Chief Commercial Officer | Conversion | +82,508 | 82,508 | ||
| 2020-11-03 | Vavricka John Chief Commercial Officer | Conversion · Series B Convertible Preferred Stock | −82,508 | 0 | ||
| 2020-10-29 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2020-10-29 | BERGER FRANKLIN M Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2020-10-29 | Polsky Bruce Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2020-10-29 | Lucidi Bruno Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2020-10-29 | Foster Wayne See Remarks | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2020-10-29 | Cheng Isaac Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2020-10-29 | Hack Andrew A. F. Director | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 |
Page 14 of 14 · 280 trades